Full-Time

Business Performance and Analytics Manager

Global Supply Chain

Updated on 8/25/2026

Deadline 11/5/26
Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Business & Strategy (2)
,
Required Skills
Power BI
Python
Supply Chain Management
Data Visualization
SQL
SAP Products
Tableau
BusinessObjects
Data Governance
Databricks
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • 8-13 years of experience in Supply Chain, Business Analytics, Data Analytics, Operations, Finance, Engineering, or related business functions, or an equivalent combination of education and relevant experience consistent with qualification requirements.
Responsibilities
  • Serve as the primary integrator of business performance across the Global Planning Network and Site Supply Chain organizations, ensuring a unified view of end-to-end supply chain performance.
  • Foster partnerships across Supply Planning, Raw Materials Planning, Digital Technology, and Site Supply Chain teams to align performance measures, priorities, and business objectives.
  • Establish common KPI definitions, reporting standards, and governance processes across global planning and site operations.
  • Connect operational, planning, and financial insights into a cohesive business performance narrative for executive decision-making.
  • Facilitate cross-functional performance reviews, resolve performance gaps, and drive aligned improvement initiatives across the global network.
  • Lead the Business Performance & Analytics team supporting the Global Planning Network and Site Supply Chain organizations.
  • Define the analytics strategy, operating model, priorities, and roadmap aligned with Global Planning objectives.
  • Establish governance for Global Supply Chain Planning KPI reporting, performance management, and business analytics.
  • Ensure timely delivery of recurring and ad hoc reporting.
  • Translate business strategy into performance metrics and executive dashboards with Global Planning.
  • Present business insights and recommendations to Planning and Site Supply Chain leadership.
  • Provide strategic analytics leadership across Supply Planning, Raw Materials Planning, Inventory Planning, and Integrated Business Planning processes.
  • Partner with planning leaders to identify trends, risks, constraints, and opportunities that improve planning performance and supply reliability.
  • Lead analytics supporting manufacturing and site supply chain operations.
  • Drive standardization of metrics and reporting processes across manufacturing sites.
  • Lead the design and continuous improvement of enterprise analytics capabilities, including executive dashboards, KPI scorecards, self-service reporting, data visualization, predictive analytics, and artificial-intelligence-enabled decision support.
  • Collaborate with the Global Supply Chain Digital team to develop and support reporting platforms including Tableau, Power BI, SAP Analytics Cloud, and other enterprise analytics tools.
  • Partner with Digital Technology and SAP teams to prioritize enhancements, improve reporting architecture, and increase automation across supply chain processes.
  • Partner with Finance to improve visibility of supply chain financial performance, including budget tracking, cost center performance, logistics costs, inventory carrying costs, scrap performance, forecast accuracy, and operational cost drivers.
  • Develop analytics that enable proactive financial decision-making and quantify business value delivered through supply chain improvements.
  • Lead initiatives to simplify processes, automate reporting, improve data quality, and standardize analytics.
  • Drive continuous improvement projects that improve operational efficiency, reporting effectiveness, and business outcomes.
  • Lead and develop the Business Performance & Analytics Analyst team.
  • Prioritize and allocate work across the team to meet business commitments.
  • Ensure consistent KPI definitions, reporting standards, and data quality across supported functions.
  • Facilitate cross-functional performance reviews and support governance forums.
  • Drive continuous improvement, automation, and analytics capability within the team.
  • Coach and develop team members while fostering a collaborative, customer-focused culture.
Desired Qualifications
  • Experience leading or supervising business analytics, business intelligence, supply chain, planning, or operations teams in a complex global organization.
  • Strong knowledge of end-to-end supply chain planning processes, including Supply Planning, Raw Materials Planning, Inventory Planning, Integrated Business Planning, Manufacturing, Procurement, Logistics, and Site Supply Chain operations.
  • Experience developing enterprise performance dashboards, KPI frameworks, executive reporting, and business performance scorecards.
  • Knowledge of SAP S/4HANA, SAP ECC, SAP Fiori, SAP IBP, Tableau, Power BI, SAP Analytics Cloud, BusinessObjects, SQL, Python, or Databricks.
  • Experience leading process improvement, reporting standardization, automation, and digital transformation initiatives.
  • Strong understanding of data governance, data quality, and master data management principles.
  • Experience partnering with Finance on business performance reporting, budgeting, forecasting, and operational performance analysis.
  • Analytical, communication, presentation, and stakeholder management skills, including the ability to translate complex data into meaningful business insights for diverse audiences.
  • Ability to lead teams, develop talent, manage competing priorities, and deliver high-quality results in a fast-paced, matrixed environment.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.